Breakthrough In Epstein-Barr Virus Antibody Research

In February 2026, researchers announced that they had moved closer to developing a vaccine against the Epstein-Barr Virus (EBV) after successfully testing newly developed monoclonal antibodies in mice.

Key Points

Widespread Infection: Nearly 95% of the global population carries EBV, which is linked to infectious mononucleosis, multiple sclerosis, certain cancers and EBV-associated lymphomas.
Targeted Antibody Development: Scientists developed 10 monoclonal antibodies targeting two key viral surface proteins- gp350 (which binds to cell receptors) and gp42 (which enables viral entry into cells).
Successful Prevention in Mice: One antibody targeting gp42 completely prevented infection in humanised mice, while another targeting gp350 offered partial protection.
Potential for High-Risk Patients: EBV-related complications are especially dangerous for immunosuppressed transplant recipients; antibody infusions may help prevent viral activation in such patients.
Step Toward Vaccine Development: Researchers described the findings as a significant step toward a future preventive vaccine against EBV.